We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-1.84%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$1.85B
AUM Growth
+$135M
Cap. Flow
-$725M
Cap. Flow %
-39.12%
Top 10 Hldgs %
58.55%
Holding
374
New
79
Increased
68
Reduced
92
Closed
116

Top Buys

Rank Stock Value
1
BIOA
BioAmber Inc.
BIOA
+$5.55M
2
IONS icon
Ionis Pharmaceuticals
IONS
+$5.2M
3
OTIC
Otonomy, Inc.
OTIC
+$3.92M
4
BLRX
BioLineRX
BLRX
+$3.37M
5
SLS icon
SELLAS Life Sciences
SLS
+$2.7M

Top Sells

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$62.4M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$59.7M
3
AMGN icon
Amgen
AMGN
+$35.8M
4
LLY icon
Eli Lilly
LLY
+$15.7M
5
BIIB icon
Biogen
BIIB
+$5.67M

Sector Composition

Rank Sector Weight
1 Healthcare 6.29%
2 Materials 0.25%
3 Financials 0.16%
4 Consumer Staples 0.04%
5 Consumer Discretionary 0.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BMY icon
26
Bristol-Myers Squibb
BMY
$129B
$13M 0.7%
239,180
-50,003
-17% -$2.74M
GWPH
27
CALL
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$13M 0.7%
1,074
+840
+359% +$103K
ALNY icon
28
PUT
Alnylam Pharmaceuticals
ALNY
$38.3B
$12.7M 0.68%
2,477
+421
+20% +$19.5K
UTHR icon
29
PUT
United Therapeutics
UTHR
$26.1B
$12.2M 0.66%
899
-201
-18% -$30.4K
SRPT icon
30
CALL
Sarepta Therapeutics
SRPT
$1.64B
$12M 0.65%
4,049
+3,438
+563% +$106K
TSRO
31
PUT
DELISTED
TESARO, Inc.
TSRO
$10.7M 0.58%
697
+134
+24% +$21.8K
IONS icon
32
PUT
Ionis Pharmaceuticals
IONS
$8.93B
$10.1M 0.55%
2,523
+1,786
+242% +$80.2K
ALNY icon
33
CALL
Alnylam Pharmaceuticals
ALNY
$38.3B
$10.1M 0.54%
1,965
+725
+58% +$33.5K
INCY icon
34
CALL
Incyte
INCY
$25.8B
$8.97M 0.48%
+671
New +$85.4K
DVAX
35
CALL
DELISTED
Dynavax Technologies
DVAX
$7M 0.38%
11,760
+9,781
+494% +$47K
SIOX
36
CALL
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$6.89M 0.37%
577
-139
-19% -$14.6K
HCA icon
37
CALL
HCA Healthcare
HCA
$88.4B
$6.67M 0.36%
750
-5,741
-88% -$479K
ALXN
38
PUT
DELISTED
Alexion Pharmaceuticals
ALXN
$6.67M 0.36%
+550
New +$70.9K
LUMO
39
PUT
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$6.33M 0.34%
+292
New +$41.7K
INCY icon
40
PUT
Incyte
INCY
$25.8B
$6.26M 0.34%
+468
New +$59.6K
AMGN icon
41
Amgen
AMGN
$209B
$6.09M 0.33%
37,104
-215,691
-85% -$35.8M
OTLK icon
42
Outlook Therapeutics
OTLK
$187M
$6M 0.32%
13,990
– –
VRTX icon
43
PUT
Vertex Pharmaceuticals
VRTX
$123B
$5.93M 0.32%
542
+246
+83% +$21.7K
LUMO
44
CALL
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$5.82M 0.31%
268
+92
+52% +$13.1K
GWPH
45
PUT
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$5.6M 0.3%
463
+271
+141% +$33.2K
SIOX
46
PUT
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$5.44M 0.29%
455
+125
+38% +$13.1K
INSM icon
47
PUT
Insmed
INSM
$22.4B
$5.36M 0.29%
3,061
+1,148
+60% +$17.7K
IONS icon
48
CALL
Ionis Pharmaceuticals
IONS
$8.93B
$5.27M 0.28%
1,311
+257
+24% +$11.5K
JAZZ icon
49
CALL
Jazz Pharmaceuticals
JAZZ
$16.1B
$4.85M 0.26%
+334
New +$43.5K
ABBV icon
50
PUT
AbbVie
ABBV
$465B
$4.65M 0.25%
714
-464
-39% -$29.2K
1
2
3 4 5

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
AB
Aozora Bank Tokyo, Japan $43.6M AUM 1.15% 1-Year Est. Return

Sabby Management's Q1 2017 Portfolio in Review

As of Q1 2017, Sabby Management held 374 positions worth $1.85B, up 7.8% from $1.72B the previous quarter. Its ten largest holdings account for 59% of the portfolio.

Sabby Management withdrew a net $725M in Q1 2017, closing 116 positions and reducing 92 holdings. Its most notable exit was Sarepta Therapeutics, an estimated $62.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 6.3% of assets, down from 18% a quarter earlier, followed by Materials and Financials.

Against the trend, Sabby Management opened a new position in BioAmber Inc. worth $3.39M.

  • Sabby Management's largest Q1 2017 buy was BioAmber Inc.: 1,460,859 shares worth $3.39M.
  • Sabby Management added most to Otonomy, Inc. in Q1 2017, an estimated $3.92M increase.
  • Sabby Management's biggest Q1 2017 reduction was Amgen, cutting an estimated $35.8M.
  • Sabby Management fully exited Sarepta Therapeutics in Q1 2017, selling an estimated $62.4M.
  • Sabby Management's ten largest holdings make up 59% of its $1.85B portfolio in Q1 2017.
  • Sabby Management opened 79 new positions and closed 116 in Q1 2017.
  • Sabby Management's portfolio value rose 7.8% quarter-over-quarter to $1.85B.

Based on Sabby Management's 13F filing for Q1 2017, filed 15 May 2017.